This excerpt taken from the ELN 6-K filed Sep 29, 2009.
the commercial success of bapineuzumab and other potential AIP products.
Under the terms of the Janssen AI Shareholders’ Agreement we are entitled to receive 49.9% of Janssen AI’s future profits and certain royalty payments from Janssen AI in respect of sales of bapineuzumab and other potential AIP products. While our profit share entitlement commences immediately upon Janssen AI becoming profitable, royalties will generally only arise after Johnson & Johnson has earned profits from the AIP equal to its (up to) $500.0 million investment. Any such payments are dependent on the future commercial success of bapineuzumab and other potential AIP products. If no drug is commercially successful, we may not receive any profit or royalty payments from Janssen AI.